ABC News reports:
Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead.
Advisers to the FDA will publicly debate the evidence next week. If the agency ultimately authorizes the shots, the Centers for Disease Control and Prevention will make the final decision on who should receive them.
Read the full article.
Pfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing infections in elementary school children. https://t.co/vmE3BVKD9p
— The Associated Press (@AP) October 22, 2021